home edit2 whole TSD November 2002 PDF format - OEHHA

p-CRESIDINE
CAS No: 120-71-8
I. PHYSICAL AND CHEMICAL PROPERTIES (From HSDB, 1994)
Molecular weight 137.20
Boiling point 235 °C
Melting point 51.5 °C
Vapor pressure
not available
Air concentration conversion 1 ppm = 5.611 mg/m 3
II.
HEALTH ASSESSMENT VALUES
Unit Risk Factor: 4.3 E-5 (µg/m 3 ) -1
Slope Factor: 1.5 E-1 (mg/kg-day) -1
[Female mouse urinary bladder tumor data (NCI, 1979), contained in Gold et al. (1984),
expedited Proposition 65 methodology, with cross-route extrapolation.]
III.
CARCINOGENIC EFFECTS
Human Studies
No studies on the potential carcinogenic effects of p-cresidine in humans are known to exist.
Animal Studies
Male and female Fischer 344 (F344) rats and B6C3F 1 mice (50 animals/sex/species/group) were fed
diets containing p-cresidine (NCI, 1979). The study design is outlined in Table 1. Dose levels for male
and female mice were reduced after 21 weeks; the study report did not describe the rationale for the
dose reduction.
Mortality in mice was dose-related and associated with the development of bladder tumors; mortality in
rats was also dose-related and was related to development of urinary bladder and nasal cavity tumors.
Survival percentages after 75 weeks of treatment are listed in Table 2. Significant incidence increases
were seen for urinary bladder tumors in male and female rats (squamous-cell or transitional-cell
carcinomas) and mice (transitional-cell carcinomas), for liver tumors in female mice (hepatocellular
adenomas or carcinomas) and male rats (neoplastic liver nodules, hepatocellular carcinomas or
cholangiocarcinomas), and for nasal cavity tumors (primarily nasal cavity tumors) in male and female
rats. These data are listed in Table 2. Nonsignificant increases in nasal cavity tumors were also
observed in male and female mice.
221